An interventional study of HARMONY and Enhanced usual care in Hepatocellular Carcinoma, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Carcinoma, Hepatocellular by Massachusetts General Hospital — 3 open to participants now, 5 under way, none of them phase 3. Carcinoma, Hepatocellular · Massachusetts General Hospital.
Among the 14 studies in Carcinoma, Hepatocellular by Massachusetts General Hospital, this one has the largest planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 2 with no phase, and was the 14th registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →3 of the 14 studies in Carcinoma, Hepatocellular by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18–99
Massachusetts General Hospital · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 5
First in 2004; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is close to the median of 53 across 2,623 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 29 across the 12 interventional studies, 28 across the 2 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
2 of the studies in Carcinoma, Hepatocellular by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05096715Massachusetts General HospitalAtezolizumab+Bevacizumab+SBRT in Unresectable HCC | 2027-01-31 |
| NCT06541990Massachusetts General HospitalPsychoeducational Intervention for Patients With Hepatocellular Carcinoma | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Carcinoma, Hepatocellular by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to refine and pilot test HARMONY, a psychoeducational intervention for patients with newly diagnosed hepatocellular carcinoma (HCC).
There are two parts of this study. Study Part 1 is an open pilot study to refine HARMONY prior to larger-scale testing in a randomized controlled trial (RCT) setting. Study Part 1 is purely descriptive, as the investigators will use the data to refine HARMONY before proceeding to Study Part 2.
Study Part 2 is a pilot RCT to assess the feasibility and acceptability of conducting a randomized trial of HARMONY versus enhanced usual care. Participants will complete a baseline survey and then be randomized to HARMONY versus enhanced usual care (a supportive care resource guide). This record reflects the clinical trial component (Study Part 2), as feasibility and acceptability outcomes will be collected for this phase only.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
HARMONY is a psychoeducational intervention that consists of three one-on-one coaching sessions and a structured session workbook.
Behavioral: HARMONY
The enhanced usual care condition consists of a curated list of supportive care services for patients with HCC.
Other: Enhanced usual care
A psychoeducational intervention for patients with HCC
A supportive care resource guide
Feasibility: study enrollment rate
≥40% enrollment among consecutive eligible patients
Time frame: 10 weeks
Feasibility: intervention completion rate
≥50% completion of 2/3 intervention sessions in the HARMONY arm
Time frame: 10 weeks
Acceptability
≥70% of patients in the HARMONY arm reporting Client Satisfaction Questionnaire-8 (CSQ-8) scores at or above the midpoint score of 20 on a scale from 8-32
Time frame: 10 weeks
Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.
Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 29 months is below that.
Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Jun 2026 → Mar 2027 and completion Sep 2026 → Jun 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →